Phase II trial of pyrazofurin in patients with multiple myeloma refractory to standard cytotoxic therapy.
D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage / Q000627:therapeutic use*; D004341:Drug Evaluation; D006801:Humans; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy*; D012263:Ribonucleosides / Q000008:administration & dosage / Q000627:therapeutic use*
D000903:Antibiotics, Antineoplastic; D012263:Ribonucleosides